Insurance status is related to diffuse large B-cell lymphoma survival. - Wikidata - wikimedia - TriplyDB

Insurance status is related to diffuse large B-cell lymphoma survival.

Insurance status is related to diffuse large B-cell lymphoma survival.

http://www.wikidata.org/entity/Q50132026

about

Nonclinical Factors Associated with 30-Day Mortality after Lung Cancer Resection: An Analysis of 215,000 Patients Using the National Cancer Data Base Socioeconomic disparities in lymphoma Survival disparities by insurance type for patients aged 15-64 years with non-Hodgkin lymphoma Disease characteristics, patterns of care, and survival in very elderly patients with diffuse large B-cell lymphoma.Identifying racial differences in nodular lymphocyte-predominant Hodgkin lymphoma.Population-specific prognostic models are needed to stratify outcomes for African-Americans with diffuse large B-cell lymphoma.Breast cancer stage variation and survival in association with insurance status and sociodemographic factors in US women 18 to 64 years old.Intravascular large B-cell lymphoma in the United States (US): a population-based study using Surveillance, Epidemiology, and End Results program and National Cancer Database.Disparities in survival by insurance status in patients with Hodgkin lymphoma.Impact of delays in definitive treatment on overall survival: a National Cancer Database study of patients with Hodgkin lymphoma.Survival for patients with chronic leukemias in the US and Britain: Age-related disparities and changes in the early 21st century.Prognostic modeling in diffuse large B-cell lymphoma in the era of immunochemotherapy: Where do we go from here?Association of socioeconomic status with autologous hematopoietic cell transplantation outcomes for lymphoma.Impact of age and socioeconomic status on treatment and survival from aggressive lymphoma: a UK population-based study of diffuse large B-cell lymphoma.Older patients with early-stage diffuse large B-cell lymphoma: the role of consolidation radiotherapy after chemoimmunotherapy.

P2860

Q30982403-001EA1EE-D092-4EC0-8421-40ACEC3F172F Q33718800-73CCF31E-CA9B-4BA0-8DF9-3D25801A9958 Q35586706-D92DC31B-13DD-4AB2-BA68-40884D796AB7 Q35637806-0E213715-3717-4B21-8B1C-EADFC135A159 Q36074344-154BC9FE-7DD8-410B-B932-28C96CF1969B Q37359378-E1A76C6D-D478-4642-9EA3-791EDD121C2A Q40228854-46A038E3-ADD4-4864-9DFD-1D8642628811 Q40299540-4773434D-2D66-47E1-B6C2-C03EB2DE47AD Q40853433-F5CE0391-1F2E-402A-BC86-EF1D5C6AE6E9 Q41355259-EB625209-2EBB-4ADB-9BA6-B405FFE21D40 Q44306052-FD21CD66-849F-4666-B0A9-486A617E3102 Q48207286-759D30D8-4E00-4DCA-8952-B158A6D1F914 Q50216037-20030AAA-179B-48BB-B879-8D14740EB2EE Q50794996-6D621206-6098-42F6-A998-7561AB219647 Q53019638-7E4AF31D-BA48-4C2B-82E3-196EAAF0A8E7

P2860

Insurance status is related to diffuse large B-cell lymphoma survival.

http://www.wikidata.org/entity/Q50132026

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh-hant

name

Insurance status is related to diffuse large B-cell lymphoma survival.

@en

Insurance status is related to diffuse large B-cell lymphoma survival.

@nl

type

label

Insurance status is related to diffuse large B-cell lymphoma survival.

@en

Insurance status is related to diffuse large B-cell lymphoma survival.

@nl

prefLabel

Insurance status is related to diffuse large B-cell lymphoma survival.

@en

Insurance status is related to diffuse large B-cell lymphoma survival.

@nl

P1433

Q50132026-EF931EA4-6BC3-4103-8681-40890C7AB446

P1476

Q50132026-BF35D1F1-4702-4B9D-8020-EFDD415FAB35

P2093

Q50132026-09D5C7A7-3EC7-4EB3-8843-93B66DAA90A2

Q50132026-0BC08F29-73DF-4C70-9FDE-EB1A6875438E

Q50132026-4E32792F-1473-46D6-AA26-156266610F74

Q50132026-90827BEE-C922-412B-AFC5-08BFC60C271E

Q50132026-B47A0274-A358-483A-9A4B-067ECC15EF56

Q50132026-F7932866-FF1D-47C5-8041-F0A9FB9185D8

P2860

Q50132026-02A01A62-5CC4-48DA-BA8D-4A9A5FC6A57F

Q50132026-07C3DEDD-2B13-4C30-9AD3-9497B421C5AF

Q50132026-19833886-EE0B-4DBC-A4F8-4188920FDA85

Q50132026-2E48A309-F5F3-48BA-9368-AB17C28731A0

Q50132026-31327DB9-43BE-4BFB-A6CD-D97CDA0F504B

Q50132026-3927CF84-BD59-4D45-954C-E8B1595ED5D3

Q50132026-3FD4881B-B14C-4B50-98AE-948B55DEB2B6

Q50132026-40C22AE8-65FD-44EF-8D16-7846EC6CF0CD

Q50132026-5EB65328-1658-444A-AB63-EC52712A7915

Q50132026-89740BE3-C79D-4194-9ED0-35E254144714

P304

Q50132026-A75F9B14-B867-4E54-97E9-17C99EF05598

P31

Q50132026-ADB8829A-25DC-4E6C-8EF5-963FE3FEB420

P356

Q50132026-6494E81B-4EA3-4CD5-97B0-943467FEEEEF

P407

Q50132026-915DD715-F98C-4846-988A-6CC618E2B5A1

P433

Q50132026-31A34145-3243-485A-8A9A-E168ECB4CA59

P478

Q50132026-661D61FD-99C7-4193-86FD-BECEB3941FD9

P577

Q50132026-AF509259-B94D-4BF5-AC5C-CE924024D1BB

P5875

Q50132026-FA97AEBD-E14F-49A6-91A0-6C664968D25F

P698

Q50132026-C304A0C4-A605-4858-B088-730557A47886

P356

P1433

P1476

Insurance status is related to diffuse large B-cell lymphoma survival.

@en

P2093

Ahmedin Jemal

http://www.w3.org/2001/XMLSchema#string

Christopher R Flowers

http://www.w3.org/2001/XMLSchema#string

Elizabeth Ward

http://www.w3.org/2001/XMLSchema#string

Helmneh Sineshaw

http://www.w3.org/2001/XMLSchema#string

Loretta J Nastoupil

http://www.w3.org/2001/XMLSchema#string

Xuesong Han

http://www.w3.org/2001/XMLSchema#string

P2860

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

Association of insurance with cancer care utilization and outcomes

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

The epidemic of non-Hodgkin lymphoma in the United States: disentangling the effect of HIV, 1992-2009.

Data sources for measuring comorbidity: a comparison of hospital records and medicare claims for cancer patients.

Examining racial differences in diffuse large B-cell lymphoma presentation and survival.

Disparities in the early adoption of chemoimmunotherapy for diffuse large B-cell lymphoma in the United States.

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.

InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions.

P304

1220-1227

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.28549

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

120

http://www.w3.org/2001/XMLSchema#string

P577

2014-01-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259960750

http://www.w3.org/2001/XMLSchema#string

P698

24474436

http://www.w3.org/2001/XMLSchema#string